|
Synonyms: ARC-1905 | ARC1905 | Izervay® | Zimura
avacincaptad pegol is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Avacincaptad pegol (ARC-1905) is a pegylated RNA aptamer that selectively binds to complement C5 and prevents its cleavage into C5a and C5b. This action inhibits activation of inflammasomes and the formation of membrane attack complexes (MAC). It is a clinical lead for age-related macular degeneration.
|
| No information available. |
Summary of Clinical Use  |
| Avacincaptad pegol (ARC-1905) was progressed to clinical evaluations to determine efficacy in age-related macular degeneration (AMD) [1]. It met its primary endpoints in two studies. The FDA granted approval for the treament of geographic atrophy (secondary to AMD) in August 2023. This drug is administered as an intravitreal injection. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04435366 | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) | Phase 3 Interventional | IVERIC bio, Inc. | ||
| NCT02686658 | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Phase 2/Phase 3 Interventional | IVERIC bio, Inc. | ||
| NCT03364153 | Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) | Phase 2 Interventional | IVERIC bio, Inc. | ||
